- PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studies
- PFS results reinforced by larger number of prior treatments in Bria-IMT population than in comparable studies
- Bria-IMT PFS compares favorably to their most recent treatment PFS in 48% of patients
- Clinical benefit rate of 56% in evaluable patients
- 71% intracranial objective response rate (iORR) in heavily pretreated patients
- Findings support clinical efficacy of Bria-IMT and highlight its significant potential in managing CNS metastatic disease in advanced breast cancer
- Additional preclinical anti-cancer data of Bria-OTS+ and Bria-PROS+ will be presented tomorrow 9:00 AM - 12:30 PM PST; Abstract Presentation Number: 6753
BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.